Craig14 Jun 2018 10:26
An innovative treatment for HIV, which uses two drugs instead of the normal three, has proved effective in a major clinical trial, in a big boost for its manufacturer ViiV, a division of GlaxoSmithKline.
The trial, called Gemini, could significantly enlarge GSK's share of the $20bn a year market for HIV treatment, with analysts predicting sales of at least £1.1bn annually by 2025.